Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CTH | P32929 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25378954 | 1.00 | NR4A1 (0.46) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL25378960 | 1.00 | NR4A1 (0.46) | NR4A1MAOATOP2AMEN1NPC1 | |
| 2-Pyridinecarboxaldehyde SCHEMBL25376118 | 0.93 | NR4A1 (0.41) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL11227025 | 0.85 | NR4A1 (0.50) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL3731779 | 0.85 | NR4A1 (0.50) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL3109223 | 0.79 | NR4A1 (0.55) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL9915224 | 0.79 | NR4A1 (0.55) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL8722415 | 0.78 | NR4A1 (0.50) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL18396247 | 0.77 | NR4A1 (0.42) | NR4A1MAOATOP2AMEN1NPC1 | |
| SCHEMBL18396248 | 0.77 | NR4A1 (0.42) | NR4A1MAOATOP2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9200104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| EP-0906342-B2 | POLYMERISATION CATALYST AND PROCESS | WARWICK EFFECT POLYMERS LTD (GB) | 2015-02-11 | — | — | EP | disclosed |
| US-20130295040-A1 | POLYMER | WARWICK EFFECT POLYMERS LTD (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130295040-A1 | POLYMER | WARWICK EFFECT POLYMERS LTD (US) | 2013-11-07 | — | — | US | disclosed |
| US-8436104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8197847-B2 | Process for making polymers and supports comprising pendant sugar side groups | WARWICK EFFECT POLYMERS LTD. (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8197847-B2 | Process for making polymers and supports comprising pendant sugar side groups | WARWICK EFFECT POLYMERS LTD. (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20090082224-A1 | POLYMERS | WARWICK EFFECT POLYMERS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| US-20090082224-A1 | POLYMERS | WARWICK EFFECT POLYMERS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| US-20080300348-A1 | Polymer | WARWICK EFFECT POLYMERS LIMITED | 2008-12-04 | — | — | US | disclosed |
| US-20080300348-A1 | Polymer | WARWICK EFFECT POLYMERS LIMITED | 2008-12-04 | — | — | US | disclosed |
| WO-2007104948-A2 | POLYMERS | WARWICK EFFECT POLYMERS LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| US-20070219330-A1 | Amide initiators | WARWICK EFFECT POLYMERS LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219330-A1 | Amide initiators | WARWICK EFFECT POLYMERS LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| WO-2007083097-A1 | LIVING RADICAL POLYMERISATION PROCESS | WARWICK EFFECT POLYMERS LTD. (GB) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | NR4A1 889/4885MAOA 495/4885TOP2A 540/4885 |
| US-20130295040-A1 | POLYMER | PCNA, PARG, COASY | NR4A1 3872/4885MAOA 3764/4885TOP2A 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.